Contact hours available until 10/31/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Authors Conflict of Interest Disclosure:
The authors reported no actual or potential conflict of interest in relation to this continuing nursing education activity.

Nephrology Nursing Journal Editorial Board Statements of Disclosure:
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.

Paula Dutka MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

Carol M. Headley DNSc, ACNP-BC, RN, CNN, disclosed that she is a Consultant and/or member of the Corporate Speaker's Bureau for Sanofi Renal, and a member of the Advisory Board for Amgen.

Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a Fresenius employee, freelance editor for Lippincott Williams & Wilkins and Elsevier publishing companies, and a consultant for Symplmed.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Hazel A. Dennison, DNP, RN, APNc, CPHQ, CNE, ANNA Education Director.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses' Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910

Goal: To provide an overview of guidelines nephrology nurses and other healthcare providers can use when making decisions about renal replacement therapy in elderly nephrology patients.

Objectives

Explain how shared decision making can allow the nephrology nurse’s perspective of renal replacement therapy be heard so as to advocate for the elderly patient.
Outline recommendations as published by the Renal Physicians Association (RPA) and the American Society of Nephrology (ASN) addressing the initiation and discontinuation decisions for acute and end-stage kidney disease.
Discuss strategies nephrology nurses can employ when caring for patients and their families when facing end-of-life decisions.

Virginia Ann B. Hallock DNP, APRN, ANP-BC, CNN

Appearances